ViewRay Inc. (NASDAQ: VRAY) stock gained by 1.8% at last close while the VRAY stock-price surges in the pre-market as well by 7.8%. The MRIdian radiation treatment system is designed, manufactured, and sold by ViewRay. MRIdian is based on a patented high-definition MR imaging technology that was created from the bottom up to solve the particular difficulties and clinical processes associated with advanced radiation oncology.
VRAY stock’ Recent Past Development
UCLA Health has joined the Siteman Cancer Center at Washington University, Seoul National University Hospital, and Amsterdam UMC in treating 1,000 patients with the MRIdian MRI-guided radiation therapy system, according to ViewRay. UCLA Health is the fourth MRIdian center to achieve this medical milestone in providing cancer patients with the benefits of MRI-guided radiation therapy.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
In October 2014, UCLA Health became the third center in the world to get MRIdian technology, treating their first patient. The MRIdian Linac system, which combines MRI guidance with linear accelerator delivery, was installed at the facility in 2019. Cancers of the pancreas, liver, and prostate are all treated at UCLA Health. The SMART Trial, a multi-center, progressive clinical trial for advanced disease or borderline pancreatic cancer, was developed with UCLA Health as a significant collaborator. In the treatment of pancreatic cancer, the study investigates the therapeutic advantages of precise, high-dose radiation therapy provided by MR-guidance coupled with daily on-table modification.
Over the last decade, UCLA Health has innovated the use of SBRT in prostate cancer, and the function of MRIdian is now being validated. MIRAGE (NCT04384770), a randomized trial study of CBCT vs. MRIdian for safe SBRT for intact prostate, and the EXCALIBUR trial (NCT04915508), aimed to examine the validity of MRIdian SBRT for patients with recurrent cancer following surgery, are two clinical trials that UCLA has started.
Through diagnostic-quality MR pictures and the capacity to adjust to the targeted malignancy in real-time, the MRIdian system offers oncologists with exceptional anatomical visualization. Without depending on fiducially markers, doctors may establish strict treatment margins based on daily anatomy to enable the administration of ablative radiation doses in five or less treatment period.